Literature DB >> 20087928

Hematopoietic cell transplantation and emerging viral infections.

D Chatzidimitriou1, E Gavriilaki, I Sakellari, E Diza.   

Abstract

Viral infections remain important causes of morbidity and mortality in hematopoietic cell transplant recipients. More recent developments in preparative regimens and graft manipulations, as well as the control of well-recognized post-transplant infections by the introduction of prophylaxis and preemptive strategies, have influenced the timing and the epidemiology of infections. As new pathogens, such as human metapneumovirus (HMPV), human bocavirus, human coronaviruses HCoV-NL63 and HCoV-HKU1, human herpesviruses HHV-6 and HHV-7, and polyomaviruses, have emerged, it is fundamental to determine the significance of the newly discovered viruses and their role in the transplantation field. This article summarizes recent data on epidemiology and laboratory diagnosis of new pathogens, as well as clinical features and management of the associated infectious complications. J. Med. Virol. 82:528-538, 2010. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20087928      PMCID: PMC7166846          DOI: 10.1002/jmv.21696

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  121 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

Review 2.  Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature.

Authors:  M A Kharfan-Dabaja; E Ayala; J Greene; A Rojiani; F R Murtagh; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2006-12-04       Impact factor: 5.483

3.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

Authors:  P Ljungman; R de la Camara; C Cordonnier; H Einsele; D Engelhard; P Reusser; J Styczynski; K Ward
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

4.  Human bocavirus infection, People's Republic of China.

Authors:  Xiao-Wang Qu; Zhao-Jun Duan; Zheng-Yu Qi; Zhi-Ping Xie; Han-Chun Gao; Wen-Pei Liu; Can-Ping Huang; Fu-Wang Peng; Li-Shu Zheng; Yun-De Hou
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

5.  Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China.

Authors:  Susan S Chiu; Kwok Hung Chan; Ka Wing Chu; See Wai Kwan; Yi Guan; Leo Lit Man Poon; J S M Peiris
Journal:  Clin Infect Dis       Date:  2005-05-10       Impact factor: 9.079

6.  Association between a novel human coronavirus and Kawasaki disease.

Authors:  Frank Esper; Eugene D Shapiro; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  J Infect Dis       Date:  2005-01-14       Impact factor: 5.226

7.  Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand.

Authors:  Alicia M Fry; Xiaoyan Lu; Malinee Chittaganpitch; Teresa Peret; Julie Fischer; Scott F Dowell; Larry J Anderson; Dean Erdman; Sonja J Olsen
Journal:  J Infect Dis       Date:  2007-02-16       Impact factor: 5.226

8.  Polyomaviruses KI and WU in immunocompromised patients with respiratory disease.

Authors:  Thomas Mourez; Anne Bergeron; Patricia Ribaud; Catherine Scieux; Régis Peffault de Latour; Abdellatif Tazi; Gérard Socié; François Simon; Jérôme LeGoff
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

9.  Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from Pneumocystis pneumonia.

Authors:  Andreas Müller; Dennis Klinkenberg; Jörg Vehreschild; Oliver Cornely; Ramona Liza Tillmann; Caspar Franzen; Arne Simon; Oliver Schildgen
Journal:  J Infect       Date:  2009-02-10       Impact factor: 6.072

Review 10.  Newly discovered respiratory viruses: significance and implications.

Authors:  Jeffrey S Kahn
Journal:  Curr Opin Pharmacol       Date:  2007-08-06       Impact factor: 5.547

View more
  6 in total

1.  T-cell therapy for viral infections following transplantation: why stop at three viruses?

Authors:  John A Barrett
Journal:  Mol Ther       Date:  2012-08       Impact factor: 11.454

2.  Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.

Authors:  Ross Perko; Guolian Kang; Anusha Sunkara; Wing Leung; Paul G Thomas; Mari H Dallas
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-16       Impact factor: 5.742

Review 3.  Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Justyna Ogonek; Mateja Kralj Juric; Sakhila Ghimire; Pavankumar Reddy Varanasi; Ernst Holler; Hildegard Greinix; Eva Weissinger
Journal:  Front Immunol       Date:  2016-11-17       Impact factor: 7.561

4.  Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation.

Authors:  A Egli; C Bucher; A Dumoulin; M Stern; A Buser; L Bubendorf; M Gregor; P Servida; G Sommer; J Bremerich; A Gratwohl; N Khanna; A F Widmer; M Battegay; M Tamm; H H Hirsch; J P Halter
Journal:  Infection       Date:  2012-07-18       Impact factor: 3.553

Review 5.  Antiviral T-cell therapy.

Authors:  Ann M Leen; Helen E Heslop; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

6.  Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?

Authors:  Jin Park; Sung Hee Lim; Se Hyung Kim; Jina Yun; Chan Kyu Kim; Sang Cheol Lee; Jong Ho Won; Dae Sik Hong; Seong Kyu Park
Journal:  Korean J Intern Med       Date:  2020-04-21       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.